Back to the article

HealthRX.com · Printable medication review sheet

Older-adult medication review sheet to bring to a clinician before any MOTS-c use

Age itself is not the question; kidney and liver function, frailty, other diagnoses and the medicine list are. Fill this in with your results and medicines so a clinician can see which of these unstudied variables apply to you.

Companion to “MOTS-c After 65: What Geriatric Safety Evidence Is Missing” · healthrx.com/mots-c/geriatric-safety · Facts checked 2026-10-18

Your health picture

Age
Latest kidney result (eGFR) and its date
Latest liver tests and their date
Falls in the past yearnumber, and any injury
Memory or thinking concernsyour own or a family member's observation
Weight change in the past 6 months
Long-term conditions

Every medicine and supplement you take

Include eye drops, inhalers, injections, vitamins and anything bought without a prescription.

NameAmount and how oftenWhat it is forWho prescribed it

The MOTS-c product in question

Name and salt form on the label
Where it came from
Who suggested it, and for what goal

Where the evidence stands for people 65 and older

  • ICH E7 defines the geriatric population as 65 and older and asks drug programs to seek patients 75 and above where possible.[1]
  • The only registered MOTS-c trial enrolls ages 18 to 65 and has posted no results.[2]
  • FDA identified no clinical studies with pharmacokinetic data for MOTS-c, so nothing is known about how age, kidneys or liver change exposure.[3]
  • The human exercise study measured the body's own MOTS-c in 10 young men with a mean age of 24.5; none of them received MOTS-c.[4]

Questions to ask

  1. Which of my medicines would be hardest to interpret if a new symptom appeared?
  2. Do my kidney or liver results add uncertainty here, given that no study measured MOTS-c exposure in anyone?
  3. Is there an approved treatment with data in people my age for the goal I have?
  4. What would make you advise me to stop, and who would I call?
  5. Who tested this product's identity and purity, and can I see the certificate?
Sources for the facts on this sheet
  1. International Council for Harmonisation. ICH E7: Studies in Support of Special Populations: Geriatrics (Step 4, 24 June 1993). Accessed 2026-10-18. https://database.ich.org/sites/default/files/E7_Guideline.pdf
  2. U.S. National Library of Medicine, ClinicalTrials.gov (API v2 record). NCT07505745: A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Pharmacodynamics of MOTS-c (a Mitochondrial-Derived Peptide) in Adults With Prediabetes and Overweight/Obesity. Accessed 2026-10-18. https://clinicaltrials.gov/api/v2/studies/NCT07505745
  3. U.S. Food and Drug Administration. FDA Briefing Document: MOTS-c-Related Bulk Drug Substances (MOTS-c (free base) and MOTS-c acetate), Pharmacy Compounding Advisory Committee, July 23-24, 2026. Accessed 2026-10-18. https://www.fda.gov/media/193347/download
  4. Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun 2021. PMID 33473109. https://pubmed.ncbi.nlm.nih.gov/33473109/

This sheet records information for a conversation with your prescriber or pharmacist. It does not replace their instructions or the medication's prescribing information.